Chemical structural novelty: on-targets and off-targets.

Drug structures may be quantitatively compared based on 2D topological structural considerations and based on 3D characteristics directly related to binding. A framework for combining multiple similarity computations is presented along with its systematic application to 358 drugs with overlapping pharmacology. Given a new molecule along with a set of molecules sharing some biological effect, a single score based on comparison to the known set is produced, reflecting either 2D similarity, 3D similarity, or their combination. For prediction of primary targets, the benefit of 3D over 2D was relatively small, but for prediction of off-targets, the added benefit was large. In addition to assessing prediction, the relationship between chemical similarity and pharmacological novelty was studied. Drug pairs that shared high 3D similarity but low 2D similarity (i.e., a novel scaffold) were shown to be much more likely to exhibit pharmacologically relevant differences in terms of specific protein target modulation.

[1]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[2]  P. Bork,et al.  A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.

[3]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[4]  L. Laurén,et al.  Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. , 1988, Pharmacology & toxicology.

[5]  Ajay N. Jain,et al.  Effects of inductive bias on computational evaluations of ligand-based modeling and on drug discovery , 2008, J. Comput. Aided Mol. Des..

[6]  Ajay N. Jain,et al.  Molecular Shape and Medicinal Chemistry: A Perspective , 2010, Journal of medicinal chemistry.

[7]  B. Silvestrini Beyond the limits of typical antidepressants , 2004, Psychopharmacology.

[8]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[9]  Glenn Shafer,et al.  The combination of evidence , 1986, Int. J. Intell. Syst..

[10]  R. Kuhn The treatment of depressive states with G 22355 (imipramine hydrochloride). , 1958, The American journal of psychiatry.

[11]  Gert Vriend,et al.  Collecting and harvesting biological data: the GPCRDB and NucleaRDB information systems , 2001, Nucleic Acids Res..

[12]  Xi Chen,et al.  The Binding Database: data management and interface design , 2002, Bioinform..

[13]  Anne W. Schmidt,et al.  Separation of alpha 1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. , 1991, Journal of medicinal chemistry.

[14]  Elliott Richelson,et al.  Studies on Muscarinic Binding Sites in Human Brain Identified with [3H]Pirenzepine , 1986, Journal of neurochemistry.

[15]  E. Brown,et al.  The Medical Dictionary for Regulatory Activities (MedDRA) , 1999, Drug safety.

[16]  Ajay N. Jain,et al.  Customizing scoring functions for docking , 2008, J. Comput. Aided Mol. Des..

[17]  J Coupet,et al.  Interaction of amoxapine with muscarinic cholinergic receptors: an in vitro assessment. , 1985, European journal of pharmacology.

[18]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[19]  J. Overall,et al.  CONTROLLED COMPARISON OF AMITRIPTYLINE, IMIPRAMINE AND PLACEBO IN HOSPITALIZED DEPRESSED PATIENTS , 1964, The Journal of nervous and mental disease.

[20]  Ajay N. Jain,et al.  Parameter estimation for scoring protein-ligand interactions using negative training data. , 2006, Journal of medicinal chemistry.

[21]  S. Mascarella,et al.  Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. , 1998, Journal of medicinal chemistry.

[22]  R. Mach,et al.  N-hydroxyalkyl derivatives of 3 beta-phenyltropane and 1-methylspiro[1H-indoline-3,4'-piperidine]: vesamicol analogues with affinity for monoamine transporters. , 1997, Journal of medicinal chemistry.

[23]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[24]  Ajay N. Jain,et al.  Robust ligand-based modeling of the biological targets of known drugs. , 2006, Journal of medicinal chemistry.

[25]  Meir Glick,et al.  Prediction of Biological Targets for Compounds Using Multiple-Category Bayesian Models Trained on Chemogenomics Databases , 2006, J. Chem. Inf. Model..

[26]  Darren R. Flower,et al.  On the Properties of Bit String-Based Measures of Chemical Similarity , 1998, J. Chem. Inf. Comput. Sci..

[27]  Ajay N. Jain Morphological similarity: A 3D molecular similarity method correlated with protein-ligand recognition , 2000, J. Comput. Aided Mol. Des..

[28]  G. Gintant,et al.  Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. , 2004, Journal of molecular and cellular cardiology.

[29]  Ajay N. Jain,et al.  Ligand-based structural hypotheses for virtual screening. , 2004, Journal of medicinal chemistry.

[30]  Christoph Steinbeck,et al.  Chemical Entities of Biological Interest: an update , 2009, Nucleic Acids Res..

[31]  Yvonne C. Martin,et al.  Application of Belief Theory to Similarity Data Fusion for Use in Analog Searching and Lead Hopping , 2008, J. Chem. Inf. Model..

[32]  Tudor I. Oprea,et al.  ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..

[33]  J. Enokizono,et al.  Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective alpha(2C)-adrenergic receptor antagonists. , 2007, Bioorganic & medicinal chemistry letters.

[34]  E. R. Whittemore,et al.  Antagonism of N-methyl-D-aspartate receptors by sigma site ligands: potency, subtype-selectivity and mechanisms of inhibition. , 1997, The Journal of pharmacology and experimental therapeutics.

[35]  Bin Chen,et al.  Gaining Insight into Off-Target Mediated Effects of Drug Candidates with a Comprehensive Systems Chemical Biology Analysis , 2009, J. Chem. Inf. Model..

[36]  J. A. Jablonowski,et al.  The first potent and selective non-imidazole human histamine H4 receptor antagonists. , 2003, Journal of medicinal chemistry.

[37]  S. Snyder,et al.  Structural determinants of sigma receptor affinity. , 1987, Molecular pharmacology.